title: Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy.
authors.forename: Sally
authors.initials: S
authors.lastname: Moore
authors.forename: Karl
authors.initials: K
authors.lastname: Peggs
authors.forename: Kirsty
authors.initials: K
authors.lastname: Thomson
authors.forename: Lisa
authors.initials: L
authors.lastname: Lowry
authors.forename: Antonia
authors.initials: A
authors.lastname: Ljubic
authors.forename: Anthony H
authors.initials: AH
authors.lastname: Goldstone
authors.forename: David C
authors.initials: DC
authors.lastname: Linch
authors.forename: Kirit M
authors.initials: KM
authors.lastname: Ardeshna
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000401:mortality / Q000628:therapy*; D011241:Prednisone / Q000627:therapeutic use; D012008:Recurrence; D000069283:Rituximab; D016879:Salvage Therapy; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone